CDT Equity (CDT) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDT | PBM |
|---|---|---|
| Share price | $0.7148 | $4.99 |
| Market cap | $28.98K | — |
| 1-day change | -10.65% | -2.49% |
| YTD return | — | -82.59% |
| 1-year return | — | -97.05% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $90,812.50 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28,400.00 | $150.78 |
| 52-week low | $0.70 | $1.92 |
| Distance from 52-week high | -100.00% | -96.69% |
| Average volume | 188.27K | 94.85K |
| Shares outstanding | 40.54K | — |
| Employees | 4 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CDT Equity
CDT stock →CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
CDT vs PBM FAQ
Are CDT Equity and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.